دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Technology and health inequities in diabetes care: How do we widen access to underserved populations and utilize technology to improve outcomes for all?
Osagie Ebekozien MD, Kathryn Fantasia MD, Farnoosh Farrokhi MD, Ashutosh Sabharwal PhD, David Kerr MBChB
doi : 10.1111/dom.15470
What is meant by ‘integrated personalized diabetes management’: A view into the future and what success should look like
Nick Guldemond MD
doi : 10.1111/dom.15476
Person-reported outcomes in diabetes care: What are they and why are they so important?
Norbert Hermanns PhD, Bernhard Kulzer PhD, Dominic Ehrmann PhD
doi : 10.1111/dom.15471
The role of real-time continuous glucose monitoring in diabetes management and how it should link to integrated personalized diabetes management
Monika Reddy PhD, Nick Oliver FRCP
doi : 10.1111/dom.15504
Front Cover
Thomas Eissing PhD, Sebastiaan Camiel Goulooze PhD, Paul van den Berg MSc, Martijn van Noort PhD, Martijn Ruppert MSc, Nelleke Snelder PhD, Dirk Garmann PhD, Joerg Lippert PhD, Roland Heinig PhD, Meike Brinker MD, Hiddo J. L. Heerspink PhD
doi : 10.1111/dom.15489
Efficacy of adipose-derived mesenchymal stem cell therapy in the treatment of chronic micro- and macrovascular complications of diabetes
Agnieszka Mikłosz PhD, Adrian Chabowski PhD
doi : 10.1111/dom.15375
The application of organoid models in research into metabolic diseases
Yufan Song MD, Sumei Lu MD, Fei Gao MD, Tianshu Wei MD, Wanshan Ma MD
doi : 10.1111/dom.15390
Sex-specific associations between skeletal muscle mass and incident diabetes: A population-based cohort study
Dan Liu PhD, Nan Li MS, Yiling Zhou MS, Miye Wang MS, Peige Song PhD, Changzheng Yuan PhD, Qingyang Shi MS, Hui Chen BS, Kaixin Zhou PhD, Huan Wang PhD, Tao Li PhD, Xiong-Fei Pan PhD, Haoming Tian MS, Sheyu Li MD … See fewer authorsÂ
doi : 10.1111/dom.15373
Moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with metabolic syndrome and atherosclerotic cardiovascular disease: A post-hoc analysis of the RACING trial
Yong-Joon Lee MD, Sang-Hyup Lee MD, Seng Chan You MD, Yong-ho Lee MD, Seung-Jun Lee MD, Sung-Jin Hong MD, Chul-Min Ahn MD, Byeong-Keuk Kim MD, Young-Guk Ko MD, Donghoon Choi MD, Myeong-Ki Hong MD, Yangsoo Jang MD, Jung-Sun Kim MD … See fewer authors
doi : 10.1111/dom.15374
Associations between complexity of glucose time series and cognitive function in adults with type 2 diabetes
Congcong Yu BS, Yaxin Wang MD, Bing Zhang PhD, Xiang Xu MD, Wen Zhang PhD, Qun Ding MD, Yingwen Miao PhD, Yinjiao Hou MD, Xuelin Ma BS, Tianyu Wu BS, Sijue Yang MD, Linqing Fu BS, Zhou Zhang PhD, Jian Zhou PhD, Yan Bi PhD … See fewer authorsÂ
doi : 10.1111/dom.15376
Advancing type 2 diabetes therapy with iGlarLixi in older people: Pooled analysis of four randomized controlled trials
Medha Munshi MD, Robert Ritzel MD, Edward B Jude MD, Terry Dex PharmD, Lydie Melas-Melt MSc, Julio Rosenstock MD
doi : 10.1111/dom.15377
Association of five diet scores with severe NAFLD incidence: A prospective study from UK Biobank
Fanny Petermann-Rocha PhD, Fernanda Carrasco-Marin MSc, Jirapitcha Boonpor MSc, Solange Parra-Soto MSc, Oliver Shannon PhD, Fiona Malcomson PhD, Nathan Phillips MSc, Mahek Jain MSc, Salil Deo MD, Katherine M. Livingstone PhD, Sara E. Dingle MSc, John C. Mathers PhD, Ewan Forrest MD, Frederick K. Ho PhD, Jill P. Pell MD, Carlos Celis-Morales PhD … See fewer authorsÂ
doi : 10.1111/dom.15378
Does high-normal blood pressure lead to excess cardiovascular disease events and deaths in Chinese people? A post-hoc analysis of the 30-year follow-up of the Da Qing IGT and Diabetes Study
Haixu Wang MD, Siyao He MD, Jinping Wang MD, Yali An MD, Xuan Wang RN, Guangwei Li MD, Ningling Sun MD, Qiuhong Gong MD, for the Da Qing Diabetes Prevention Outcome Study Group
doi : 10.1111/dom.15379
Ethnic disparities in cardiovascular and renal responses to canagliflozin between Asian and White patients with type 2 diabetes mellitus: A post hoc analysis of the CANVAS Program
Xi Chen Msc, Xingyun Hou MMed, Junling Gao PhD, Xiaxia Yu PhD, Weixian Zeng MMed, Ronggui Lv MMed, Xixiao Yang PhD, Yong Liu PhD
doi : 10.1111/dom.15380
Glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: A systematic review and meta-analysis of randomized controlled trials
Giovanni Antonio Silverii MD, Matteo Monami PhD, Marco Gallo MD, Alberto Ragni MD, Francesco Prattichizzo PhD, Valerio Renzelli MD, Antonio Ceriello MD, Edoardo Mannucci MD
doi : 10.1111/dom.15382
Safety, pharmacokinetics and pharmacodynamics of HRS-7535, a novel oral small molecule glucagon-like peptide-1 receptor agonist, in healthy participants: A phase 1, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose, and food effect trial
Jingying Wu MM, Renpeng Zhou PhD, Qian Zhang MM, Qin Zhang MM, Huiling Qin MM, Zi Ye PhD, Yimei Xu MD, Sheng Feng PhD, Chang Shu MM, Yu Shen PhD, Yang Fan MM, Quanren Wang PhD, Yijun Du PhD, Wei Hu PhD … See fewer authorsÂ
doi : 10.1111/dom.15383
Efficacy and safety of semaglutide 2.4 mg for weight loss in overweight or obese adults without diabetes: An updated systematic review and meta-analysis including the 2-year STEP 5 trial
Wenhui Qin MMed, Jun Yang BMed, Chao Deng MMed, Qinjuan Ruan BMed, Kai Duan MMed
doi : 10.1111/dom.15386
Pharmacokinetics and pharmacodynamics of finerenone in patients with chronic kidney disease and type 2 diabetes: Insights based on FIGARO-DKD and FIDELIO-DKD
Thomas Eissing PhD, Sebastiaan Camiel Goulooze PhD, Paul van den Berg MSc, Martijn van Noort PhD, Martijn Ruppert MSc, Nelleke Snelder PhD, Dirk Garmann PhD, Joerg Lippert PhD, Roland Heinig PhD, Meike Brinker MD, Hiddo J. L. Heerspink PhD
doi : 10.1111/dom.15387
The MiniMed 780G automated insulin delivery system adapts to substantial changes in daily routine: Lessons from real world users during Ramadan
Mohammed E. Al-Sofiani MD, Goran Petrovski MD, Abdulrahman Al Shaikh MD, Abdullah Alguwaihes MD, Mohammad Al Harbi MD, Dabia Al Mohannadi MD, Alero Adjene MD, Abdulmoeen Alagha MD, Sareea Al Remeithi MD, Naji Alamuddin MD, Arcelia Arrieta MSc, Javier Castañeda MSc, Wael Chaar PharmD, Tim van den Heuvel PhD, Ohad Cohen MD
doi : 10.1111/dom.15389
The OPTIFAST total and partial meal replacement programme reduces cardiometabolic risk in adults with obesity: Secondary and exploratory analysis of the OPTIWIN study
Jamy D. Ard MD, Ian J. Neeland MD, Amy E. Rothberg MD, Robert J. Chilton MD, Daniel de Luis MD, Sarah S. Cohen PhD, Odd Erik Johansen PhD
doi : 10.1111/dom.15392
Glycaemic control efficacy of switching from dipeptidyl peptidase-4 inhibitors to oral semaglutide in subjects with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 2 study)
Sho Furusawa MD, Hiroshi Nomoto MD, Hiroki Yokoyama MD, Yuka Suzuki MD, Atsushi Tsuzuki MD, Kiyohiko Takahashi MD, Aika Miya MD, Hiraku Kameda MD, Kyu Yong Cho MD, Jun Takeuchi MD, So Nagai MD, Shinji Taneda MD, Yoshio Kurihara MD, Akinobu Nakamura MD, Tatsuya Atsumi MD, on behalf of SWITCH-SEMA 2 study group
doi : 10.1111/dom.15393
Meta-analysis of risk of major adverse cardiovascular events in adults with type 2 diabetes treated with bexagliflozin
John J. V. McMurray MD, Scott D. Solomon MD, J. Paul Lock MD, Joseph M. Massaro PhD, Fang Zhu PhD, Wenjiong Zhou PhD, Hicham Skali MD, Eldrin F. Lewis MD, Mason W. Freeman MD, Yuan-Di C. Halvorsen PhD … See fewer authorsÂ
doi : 10.1111/dom.15394
Alanine to glycine ratio is a novel predictive biomarker for type 2 diabetes mellitus
Kwang Seob Lee MD, Yong-ho Lee MD, Sang-Guk Lee MD
doi : 10.1111/dom.15395
Glucagon-like peptide-1 analogues in monogenic syndromic obesity: Real-world data from a large cohort of Alström syndrome patients
Sadaf Ali MRCP, Shanat Baig PhD, Subadra Wanninayake MD, Gabriela da Silva Xavier PhD, Charlotte Dawson PhD, Richard Paisey MRCP, Tarekegn Geberhiwot PhD
doi : 10.1111/dom.15398
Comparative effectiveness of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors on liver function in patients with type 2 diabetes in Japan: A real-world data analysis
Hirokazu Takahashi MD, Keiko Asakawa PhD, Yoshinori Kosakai MSc, Takumi Lee BPharm, Mitsuhiro Rokuda PhD
doi : 10.1111/dom.15399
Impact of weight loss and weight gain trajectories on body composition in a population at high risk of type 2 diabetes: A prospective cohort analysis
T. Yates PhD, G. J. H. Biddle PhD, J. Henson PhD, C. L. Edwardson PhD, F. Arsenyadis MSc, L. M. Goff PhD, D. Papamargaritis PhD, D. R. Webb PhD, K. Khunti PhD, M. J. Davies MD
doi : 10.1111/dom.15400
Clinical effectiveness and cost-impact after 2 years of a ketogenic diet and virtual coaching intervention for patients with diabetes
Kiersten L. Strombotne PhD, Jessica Lum MA, Steven D. Pizer PhD, Stuart Figueroa MSW, Austin B. Frakt PhD, Paul R. Conlin MD
doi : 10.1111/dom.15401
Weight loss and treatment patterns in a real-world population of adults receiving liraglutide 3.0 mg for weight management in routine clinical practice in Switzerland (ADDRESS study)
Bernd Schultes MD, Katharina Timper MD, Gionata Cavadini PhD, Josefine Rüh MSc, Philipp A. Gerber MD
doi : 10.1111/dom.15403
The impact of increased hepatic glucose production caused by empagliflozin on plasma glucose concentration in individuals with type 2 diabetes and nondiabetic individuals
Siham Abdelgani MD, Ahmed Khattab MD, John Adams MD, Gozde Baskoy MD, Curtis Triplitt PharmD, Ralph A. DeFronzo MD, Muhammad Abdul-Ghani MD
doi : 10.1111/dom.15404
Effect of sodium-glucose cotransporter-2 inhibitors on myocardial infarction incidence: A systematic review and meta-analysis of randomized controlled trials and cohort studies
Xiaoru Huang PhD, Estau Dannya MPharm, Xuening Liu PhD, Yang Yu MPharm, Panhui Tian MPharm, Zijian Li PhD
doi : 10.1111/dom.15405
Future diabetes risk can be predicted by the number of abnormal oral glucose tolerance test values during pregnancy
Noa Tsur MD, Rena Pollack MD, Meir Frankel MD, Anat Tsur MD
doi : 10.1111/dom.15406
Efficacy of noiiglutide injection on body weight in obese Chinese adults without diabetes: A multicentre, randomized, double-blind, placebo-controlled, phase 2 trial
Yijun Li MD, Zhifeng Cheng MD, Weiping Lu MD, Ping Li BS, Hongwei Jiang MD, Jing Yang MD, Jing Xu MM, Cheng Zhang MD, Lili Zhang MD, Yao Wang MD, Fang Bian BS, Weiying Guo MD, Xuefeng Yu MD, Xiaopan Chen MM, Dong Zhao MD, Bo Feng MD, Shen Qu MD, Jie Qin MD, Yifei Zhang PhD, Lin Wang MM, Hong Cheng MD, Yiming Mu MD … See fewer authorsÂ
doi : 10.1111/dom.15407
Efficacy and safety of once-weekly insulin icodec in type 2 diabetes: A meta-analysis of ONWARDS phase 3 randomized controlled trials
Sahana Shetty MD, Renuka Suvarna MSc
doi : 10.1111/dom.15408
Glycated haemoglobin, HOMA2-B, C-peptide to glucose ratio and type 2 diabetes clusters as predictors for therapy failure in individuals with type 2 diabetes without insulin therapy: A registry analysis
Faisal Aziz PhD, Christoph Sternad MD, Caren Sourij MD, Lisa Knoll MPH, Harald Kojzar BSc, Anna Schranz, Alexandra Bürger, Harald Sourij MBA, Felix Aberer MD
doi : 10.1111/dom.15409
Effect of tirzepatide on albuminuria levels and renal function in patients with type 2 diabetes mellitus: A systematic review and multilevel meta-analysis
Paschalis Karakasis MD, Dimitrios Patoulias PhD, Nikolaos Fragakis PhD, Aleksandra Klisic PhD, Manfredi Rizzo PhD
doi : 10.1111/dom.15410
Impact of hybrid closed-loop insulin delivery on cardiac rhythm in older adults with type 1 diabetes: A post hoc analysis of trial data
Hood Thabit PhD, Charlotte Boughton PhD, Womba Mubita RN, Jose Rubio RN, Stuart Allen MSc, Robert Heugh BSc, Julia K. Mader MD, Parth Narendran PhD, Mark Evans MD, Lalantha Leelarathna PhD, Malgorzata E. Wilinska PhD, Catherine Fullwood PhD, Clifford Garratt MD, Roman Hovorka PhD, Martin K. Rutter MD
doi : 10.1111/dom.15366
Factors associated with the uric acid-lowering effects of sodium-glucose cotransporter-2 inhibition in patients with type 2 diabetes: Insights from the randomized PROTECT trial
Yuichi Saito MD, Atsushi Tanaka MD, Takumi Imai PhD, Shin-Ichiro Miura MD, Masayoshi Ajioka MD, Kazuhisa Kodama MD, Yoshio Kobayashi MD, Koichi Node MD, on behalf of the PROTECT Investigators
doi : 10.1111/dom.15368
Evaluation of the efficacy of a combination of dapagliflozin and lobeglitazone on glucose concentrations and body fat in patients with type 2 diabetes: Location-F study
Hun Jee Choe MD, He Ran Oh RN, Dawei Bu PhD, Ningyan An PhD, Philipp E. Scherer PhD, Zhiqiang An PhD, Soo Lim MD
doi : 10.1111/dom.15388
Insulin, hypoglycaemia and dementia: A causal mediation analysis showcasing challenges and potential opportunities
Wajd Alkabbani PhD, Colleen J. Maxwell PhD, Ruth Ann Marrie PhD, Suzanne L. Tyas PhD, Iliana C. Lega MD, John-Michael Gamble PhD
doi : 10.1111/dom.15385
An assessment of factors contributing to the decline in risk of stroke complicating type 2 diabetes: The Fremantle Diabetes Study
Timothy M. E. Davis FRACP, Wendy A. Davis PhD
doi : 10.1111/dom.15391
Once-weekly semaglutide reduces the risk of cardiovascular events in people with type 2 diabetes and polyvascular disease: A post hoc analysis
Ofer Kobo MD, Matthew A. Cavender MD, Thomas Jon Jensen MD, Anja Birk Kuhlman MD, Søren Rasmussen PhD, Subodh Verma MD
doi : 10.1111/dom.15396
Smartwatches for non-invasive hypoglycaemia detection during cognitive and psychomotor stress
Martin Maritsch PhD, Simon Föll PhD, Vera Lehmann MD, Naïma Styger BSc, Caterina Bérubé PhD, Mathias Kraus PhD, Stefan Feuerriegel PhD, Tobias Kowatsch PhD, Thomas Züger MD, Elgar Fleisch PhD, Felix Wortmann PhD, Christoph Stettler MD … See fewer authorsÂ
doi : 10.1111/dom.15402
Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes
Edward Pratt MD
doi : 10.1111/dom.15372
A comment on tirzepatide versus glucagon-like peptide-1 receptor agonists and heart rate with regard to ‘Impact of a dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist tirzepatide on heart rate among patients with type 2 diabetes: A systematic review and pairwise and network meta-analysis’
Ronald M. Goldenberg MD
doi : 10.1111/dom.15381
Impact of sedentary behaviour on glucose concentration in people with type 1 diabetes
Linda C. A. Drenthen MD, Mandala Ajie MSc, Steven Teerenstra PhD, Evertine J. Abbink PhD, Esmée A. Bakker PhD, Dick H. J. Thijssen PhD, Cees J. Tack PhD, Bastiaan E. de Galan PhD
doi : 10.1111/dom.15397
